COMPANY PROFILE

Solstice Neurosciences

Explore full profile

Developing, licensing, and marketing specialty pharmaceutical products to improve patient lives and community health

San Francisco, United StatesFounded 2003Biotech & Life Sciences

Valuation $25–50M Last recorded · 2010

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Solstice Neurosciences

Solstice Neurosciences, a subsidiary of US WorldMeds, operates in the specialty pharmaceutical sector, focusing on developing, licensing, and marketing healthcare products that address unmet medical needs. The company primarily serves patients with neurological conditions, offering treatments that improve quality of life and patient outcomes. Solstice Neurosciences operates within the broader pharmaceutical market, targeting niche segments with high demand for innovative therapies. The business model revolves around the development and commercialization of proprietary drugs, generating revenue through product sales and licensing agreements. By maintaining a strong pipeline of new products and leveraging strategic partnerships, Solstice Neurosciences aims to sustain growth and deliver value to patients, employees, and shareholders. The company emphasizes a culture of integrity, creativity, and action, ensuring sustainable operations and a commitment to community health.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2003
Headquarters: San Francisco, United States
Employees: 28
Open positions: None listed
Dealroom signal: 35.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b, b2c
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Aug 2010	$36M	$36M	US WorldMeds	—
SERIES BOther financing	Nov 2006	$85M	$340M	Highland Capital Partners	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Solstice Neurosciences website traffic

Latest recorded traffic for Solstice Neurosciences is 0 monthly website visits. Solstice Neurosciences's team declined 3.4% over the past year.

Latest monthly visits0 1-year team growth-3.4%

Monthly website visitsDec 2018–May 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MIMetrodora InstituteA medical and research center dedicated to advancing care and accelerating cures for people living with neuroimmune axis disorders	Salt Lake City, United States	Operational	39	$35M	$140M
VBVibe BioBuilding a community to find and fund treatments for rare diseases	Boston, United States	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
VBVero BiotechAn emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions	Atlanta, United States	Operational
SYSydnexisBiotech & Life Sciences	Del Mar, United States	Operational
CHCabinet HealthA sustainable healthcare company, starting with over-the-counter medicine	New York City, United States	Operational
GAGalenicumProduction and distribution of pharmaceutical goods in various formats	Esplugues de Llobregat, Spain	Operational
CPCOMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions	London, United Kingdom	Operational